Amylin suffers hit as FDA's request for further trials disclosed
This article was originally published in Scrip
Executive Summary
Following concerns that the FDA has requested further trials for Amylin and Lilly's anti-diabetic GLP-1 analogue Byetta (exenatide), Amylin saw its share price drop by 10%, to close at $13.97 on December 23rd.